Stay updated with breaking news from Eric Lenze. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Authors of a newly published study on the use of an antidepressant for COVID-19 claim the drug greatly reduces hospitalizations and mortality. But some experts question whether that's really what the data show.
Fluvoxamine, typically prescribed for depression or OCD, decreased hospitalizations by 66% and reduced mortality by 91% in high-risk COVID-19 outpatients in the phase 3 TOGETHER trial.
'This is among the most important findings since the COVID pandemic began'
Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization Last Updated on May 13, 2021 Dozens of COVID patients showed no deterioration in their symptoms when treated with a drug, fluvoxamine, as per a study at the School of Medicine's Department of Psychiatry, published in The Journal of the American Medical Association. The outbreak of Coronavirus disease 2019 (COVID-19) has led patients to succumb to serious illnesses and is growing even worse as its second wave takes a toll in India. Several drugs have been under trials for repurposing them against the deadly COVID-19. ...
Despite a highlight story on 60 Minutes last month, fluvoxamine, a drug typically used to treat obsessive-compulsive disorder (OCD), is still just a brief mention in the "cytokine inhibitors" section in the For now, it makes sense. Fluvoxamine, a serotonin reuptake inhibitor (SSRI), has shown promise in two smaller studies, but larger trials have not been published yet. Even if the drug becomes a more mainstream treatment for COVID-19, one expert says any demand surge is not expected to result in shortages. COVID-19 treatment potential As 60 Minutes tells it, the first COVID-19–related f...